InpharmD

Ask us any clinical question 👩🏻‍⚕️🏥🧑🏽‍⚕️and we’ll send you an evidence-based response.🚀💊💉

[InpharmD @InpharmD]

🎗️ October is Breast Cancer Awareness Month 🎗️

In recognition of this, we will be releasing daily one-pagers this week, featuring educational literature on breast cancer.

Stay tuned for updates!

#breastcancerawareness #evidencebased #stayinformedwithInpharmD
#MedTwitter

[InpharmD @InpharmD]

This month, the following drugs were approved by the U.S Food and Drug Administration (FDA).

Read our clinical summaries on new approvals here:
https://t.co/W2XzVjUgfH

#stayinformedwithInpharmD #druginformation #evidencebased #MedTwitter

[InpharmD @InpharmD]

Exciting news! InpharmD is launching an AI Expert Series where pharmacy leaders will discuss AI's role in clinical and health system pharmacy. Stay tuned, more details to come!

#stayinformedwithInpharmD #AIinPharmacy #druginformation #evidencebased #MedTwitter

[InpharmD @InpharmD]

For our next testimonial, we had the pleasure to chat with Dr. Isha Rana, Associate Director of Ambulatory Pharmacy at Mount Sinai Health System!

We're thrilled that to help clinical teams drive evidence-based care!

#stayinformedwithinpharmd #evidencebasedmedicine #MedTwitter

[InpharmD @InpharmD]

Have you heard our latest Evidence Based Medicine (EBM) podcast? Tune in as we discuss the SURMOUNT-OSA trials assessing tirzepatide for sleep apnea:

Spotify: https://t.co/neOhV0GllC
Apple: https://t.co/UVYBxoXEBE

#druginformation #evidencebasedmedicine #MedTwitter

[InpharmD @InpharmD]

Read InpharmD's clinical summaries on newly approved FDA medications for the month of July:

AHZANTIVE® (aflibercept-mrbb) https://t.co/Aa0fp0TbIo…

PYZCHIVA® (ustekinumab-ttwe) https://t.co/qoT54STf02…

#MedTwitter #StayInformedWithInpharmD #DrugInformation #Evidencebased

[InpharmD @InpharmD]

KISUNLA™ (donanemab-azbt)
https://t.co/iawlbZXRxW

EPYSQLI™(eculizumab-aagh)
https://t.co/Jd2EFZU0as

FEMLYV™ (ethinyl estradiol and norethindrone acetate)
https://t.co/cevhDSQWsl

[InpharmD @InpharmD]

InpharmD Annual Retreat!

A huge congrats to Atlanta Tech Village on their new office in Downtown! We had a blast seeing the new location!

[InpharmD @InpharmD]

We have four new FDA approval updates this week! Read the InpharmD summaries on our blog.

1. Capvaxive™ - https://t.co/ClzXc5ydtR
2. Vigafyde™ - https://t.co/uMSp8waLQ9
3. Yimmugo® - https://t.co/QTnv62cHyi
4. Sofdra™ - https://t.co/5KXv9vkDVw

#MedTwitter #StayInpharmD

[InpharmD @InpharmD]

Single-dose rasburicase with frequent laboratory monitoring is effective in the management of TLS and offers significant cost reductions.

Read full response here: https://t.co/fLWdWYmjKL

#MedTwitter #DrugInformation

[InpharmD @InpharmD]

The FDA recently approved mRESVIA, an mRNA RSV vaccine, to protect adults aged 60 years and older from lower respiratory tract disease.

Read the InpharmD summary here: https://t.co/d8hgv0LG87

#druginformation #evidencebasedmedicine #newdrugapproval #MedTwitter

[InpharmD @InpharmD]

Have you listened to our latest podcast? In this episode, we talk about excoriation (skin-picking) disorder and potential treatment options.

Spotify – https://t.co/NsisUMCPbn

Apple – https://t.co/xpmIYeYJzR

#pharmacypodcast #druginformation #medtwitter #evidencebasedcare

[InpharmD @InpharmD]

The FDA recently approved BKEMV™, the first biosimilar referencing Soliris (eculizumab) for treating paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

Read InpharmD's summary below:
https://t.co/IvFItTnQFc

#druginformation #MedTwitter

[InpharmD @InpharmD]

The FDA recently approved YESAFILI™(aflibercept-jbvf) and OPUVIZ™(aflibercept-yszy) as interchangeable biosimilars to Eylea (aflibercept).

Read InpharmD's clinical summary here: https://t.co/qiMxcKeIZw

#druginformation #evidencebased #MedTwitter

[InpharmD @InpharmD]

In the adult population, lacosamide appears to be both safe and tolerable as an IV push at dosages up to 400 mg, with bradycardia not being a significant side effect.

Read the full InpharmD inquiry here: https://t.co/GJLl7Xk9Z4

#druginfo #evidencebased #pharmacy #MedTwitter

[InpharmD @InpharmD]

The FDA recently approved IMDELLTRA™ (tarlatamab-dlle), a bispecific T-cell engager (BiTE) for the treatment of small cell lung cancer (SCLC) that has progressed on or after platinum-based chemotherapy.

Read InpharmD's summary: https://t.co/GMSiK8seAF

#MedTwitter #DrugInfo

[InpharmD @InpharmD]

MYHIBBIN™, an oral liquid formulation of mycophenolate mofetil, is indicated to prevent organ rejection in adults and children (3 months+) with kidney, heart, or liver transplants.

Learn more here:https://t.co/jd5oivkkcf

#druginformation #evidencebased #MedTwitter

[InpharmD @InpharmD]

Case reports indicate that symptoms of rash presented over 2 to 7 days after methylphenidate administration in majority of patients

Read InpharmD's DI response here: https://t.co/vts8JPiAUF

#druginformation
#evidencebased
#MedTwitter